Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12320MR)

This product GTTS-WQ12320MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12320MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13237MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13356MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ49MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ12616MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15605MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ3231MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ7041MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ11186MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW